Arvinas, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ARVN Nasdaq 2834 www.arvinas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arvinas, Inc.

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - Feb 12th, 2026 5:00 am
Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation - Jan 12th, 2026 3:48 am
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - Dec 6th, 2025 6:05 am
How the Narrative Around Arvinas Is Shifting Amid Strategic Moves and Analyst Uncertainty - Dec 2nd, 2025 12:06 am
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - Nov 26th, 2025 5:00 am
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) - Nov 24th, 2025 5:00 am
Revisiting the Narrative for Arvinas as Analyst Views Shift with New Pipeline and Partner Risks - Nov 17th, 2025 10:10 pm
Arvinas (ARVN): Losses Accelerate 7.7% Annually, but Stock Trades at Peer-Low 1.9x Sales - Nov 5th, 2025 8:16 pm
Arvinas Inc (ARVN) Q3 2025 Earnings Call Highlights: Clinical Advancements and Strategic ... - Nov 5th, 2025 12:02 pm
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates - Nov 5th, 2025 6:20 am
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 5th, 2025 5:00 am
Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates - Nov 4th, 2025 6:40 am
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting - Nov 3rd, 2025 2:00 pm
Arvinas to Participate in Upcoming Investor Conferences - Nov 3rd, 2025 5:00 am
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 - Oct 29th, 2025 5:00 am
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 24th, 2025 2:00 pm
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Oct 23rd, 2025 8:00 am
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 22nd, 2025 2:00 pm
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Oct 22nd, 2025 8:00 am
Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet - Oct 22nd, 2025 7:55 am